June 26, 2017 08:30 AM EDT
R&D

Mati­nas Bio shares are crushed on dis­ap­point­ing PhII an­ti­fun­gal da­ta

John Carroll

Editor & Founder

Shares of Mati­nas Bio­Phar­ma $MTNB were shred­ded ear­ly Mon­day af­ter the biotech an­nounced that its lead an­ti-in­fec­tives pro­gram failed to match a main­stay in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times